@article {O{\textquoteright}Connor2021.07.08.21258700, author = {Mark J. O{\textquoteright}Connor and Alicia Huerta-Chagoya and Paula Cort{\'e}s-S{\'a}nchez and Silv{\'\i}a Bon{\`a}s-Guarch and Joanne B. Cole and David Torrents and Kumar Veerapen and Niels Grarup and Mitja Kurki and Carsten F. Rundsten and Oluf Pedersen and Ivan Brandslund and Allan Linneberg and Torben Hansen and Aaron Leong and Jose C. Florez and Josep M. Mercader}, title = {Genome-Wide Association Meta-Analysis Using a Recessive Model Illuminates Genetic Architecture of Type 2 Diabetes}, elocation-id = {2021.07.08.21258700}, year = {2021}, doi = {10.1101/2021.07.08.21258700}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objective Most genome-wide association studies (GWAS) of complex traits are performed using models with additive allelic effects. Hundreds of loci associated with type 2 diabetes have been identified using this approach. Additive models, however, can miss loci with recessive effects, thereby leaving potentially important genes undiscovered.Research Design and Methods We conducted the largest GWAS meta-analysis using a recessive model for type 2 diabetes. Our discovery sample included 33,139 cases and 279,507 controls from seven European-ancestry cohorts including the UK Biobank. We then used two additional cohorts, FinnGen and a Danish cohort, for replication. For the most significant recessive signal, we conducted a phenome-wide association study across hundreds of traits to make inferences about the pathophysiology underlying the increased risk seen in homozygous carriers.Results We identified 51 loci associated with type 2 diabetes, including five variants with recessive effects undetected by prior additive analyses. Two of the five had minor allele frequency less than 5\% and were each associated with more than doubled risk. We replicated three of the variants, including one of the low-frequency variants, rs115018790, which had an odds ratio in homozygous carriers of 2.56 (95\% CI 2.05-3.19, P=1{\texttimes}10-16) and a stronger effect in men than in women (interaction P=7{\texttimes}10-7). Colocalization analysis linked this signal to reduced expression of the nearby PELO gene, and the signal was associated with multiple diabetes-related traits, with homozygous carriers showing a 10\% decrease in LDL and a 20\% increase in triglycerides.Conclusions Our results demonstrate that recessive models, when compared to GWAS using the additive approach, can identify novel loci, including large-effect variants with pathophysiological consequences relevant to type 2 diabetes.Competing Interest StatementJ.C.F. has received consulting honoraria from Goldfinch Bio and AstraZeneca, and speaking honoraria from Novo Nordisk, AstraZeneca and Merck for research presentations over which he had full control of content. None of the other authors have conflicts of interest to declare.Funding StatementM.J.O. was supported by NIH/NIDDK award T32 DK110919. J.M.M. is supported by American Diabetes Association Innovative and Clinical Translational Award 1-19-ICTS-068. S.B.-G. was supported by FI-DGR Fellowship from FI-DGR 2013 from Ag{\`e}ncia de Gesti{\'o} d{\textquoteright}Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya) and by a {\textquoteright}Juan de la Cierva{\textquoteright} post- doctoral fellowship (MINECO;FJCI-2017-32090). J.C.F. is supported by NIDDK K24 DK110550. This project received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation programme under grant agreement No 667191. This work was also supported by grant SEV-2011-00067 of the Severo Ochoa Program, awarded by the Spanish Government. This study makes use of data generated by the Wellcome Trust Case Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113. This study also makes use of data generated by the UK10K Consortium, derived from samples from UK10K COHORT IMPUTATION (EGAS00001000713). A full list of the investigators who contributed to the generation of the data is available in www.UK10K.org. Funding for UK10K was provided by the Wellcome Trust under award WT091310. Work in the UK Biobank was done under application numbers 27892 and 31063. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk). The GTEx Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Work done in the Mass General Brigham (MGB) Biobank was conducted with approval from the MGB Institutional Review Board (study 2016P001018). The UK Biobank has obtained ethical approval covering this study from the National Research Ethics Committee (REC reference 11/NW/0382). The analysis of the 70K for T2D cohort was conducted using only publicly available data from the database of Genotypes and Phenotypes (dbGaP), study accession numbers phs000674.v1.p1, phs000091.v2.p1, phs000100.v4.p1, and phs000237.v1.p1, as well from the European Genome-phenome Archive (EGA), study ID EGAS00000000005. The Danish cohort consisted of data from five studies, all of which were approved by the Ethical Committee of Copenhagen County (Capital Region or Region of Southern Denmark) and were performed in accordance with the principles of the Declaration of Helsinki II. The Finngen Biobank was evaluated and approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this study are available within the article and its supplementary materials. Additional data are available from the corresponding author J.M.M. upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2021/07/08/2021.07.08.21258700}, eprint = {https://www.medrxiv.org/content/early/2021/07/08/2021.07.08.21258700.full.pdf}, journal = {medRxiv} }